PMID- 38024627
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 2688-6146 (Electronic)
IS  - 2688-6146 (Linking)
VI  - 4
IP  - 4
DP  - 2023 Nov
TI  - Outcomes of venetoclax combined with homoharringtonine and cytarabine in fit 
      adults patients with de novo adverse-risk acute myeloid leukaemia: A 
      single-centre retrospective analysis.
PG  - 1208-1211
LID - 10.1002/jha2.792 [doi]
AB  - Adverse-risk acute myeloid leukemia (AML) has a dismal prognosis. We aimed to 
      investigate the activity and tolerability of venetoclax combined with 
      homoharringtonine (HHT) plus cytarabine (VHA) regimen for de novo adverse-risk 
      AML. Thirteen de novo AML patients with adverse-risk factors were treated with 
      venetoclax (100 mg day 1, 200 mg day 2, 400 mg days 3-21), HHT (1 mg/m(2) days 
      1-5) and cytarabine (100 mg/m(2) days 1-5) (VHA regimen). Complete remission (CR) 
      was achieved in 11/13 patient (84.6%), all of CR responders were measurable 
      residual disease (MRD) negative detected by multi-parameter flow cytometry (MFC). 
      Grade 3-4 neutropenia, anaemia, and thrombocytopenia occurred in most patients. 
      Grade 3-4 non haematological adverse events (AEs) included febrile neutropenia 
      (4/13, 30.8%). With a median follow-up of 10 months (range 4-19), median overall 
      survival and event-free survival were not reached. VHA may be a promising and 
      well-tolerated regimen in de novo adverse-risk AML.
CI  - (c) 2023 The Authors. eJHaem published by British Society for Haematology and John 
      Wiley & Sons Ltd.
FAU - Song, Bao-Quan
AU  - Song BQ
AUID- ORCID: 0000-0003-4555-1992
AD  - National Clinical Research Center for Hematologic Diseases Jiangsu Institute of 
      Hematology The First Affiliated Hospital of Soochow University Suzhou China.
AD  - Department of Hematology Institute of Blood and Marrow Transplantation Soochow 
      University Suzhou China.
FAU - Kong, Xin
AU  - Kong X
AD  - National Clinical Research Center for Hematologic Diseases Jiangsu Institute of 
      Hematology The First Affiliated Hospital of Soochow University Suzhou China.
FAU - Pu, Yan
AU  - Pu Y
AUID- ORCID: 0000-0001-8598-5037
AD  - National Clinical Research Center for Hematologic Diseases Jiangsu Institute of 
      Hematology The First Affiliated Hospital of Soochow University Suzhou China.
FAU - Liu, Yin
AU  - Liu Y
AD  - National Clinical Research Center for Hematologic Diseases Jiangsu Institute of 
      Hematology The First Affiliated Hospital of Soochow University Suzhou China.
FAU - Zhang, Jian
AU  - Zhang J
AD  - National Clinical Research Center for Hematologic Diseases Jiangsu Institute of 
      Hematology The First Affiliated Hospital of Soochow University Suzhou China.
FAU - Wu, De-Pei
AU  - Wu DP
AD  - National Clinical Research Center for Hematologic Diseases Jiangsu Institute of 
      Hematology The First Affiliated Hospital of Soochow University Suzhou China.
AD  - Department of Hematology Institute of Blood and Marrow Transplantation Soochow 
      University Suzhou China.
FAU - Qiu, Hui-Ying
AU  - Qiu HY
AD  - National Clinical Research Center for Hematologic Diseases Jiangsu Institute of 
      Hematology The First Affiliated Hospital of Soochow University Suzhou China.
AD  - Department of Hematology Institute of Blood and Marrow Transplantation Soochow 
      University Suzhou China.
LA  - eng
PT  - Journal Article
DEP - 20231101
PL  - United States
TA  - EJHaem
JT  - EJHaem
JID - 101761942
PMC - PMC10660102
OTO - NOTNLM
OT  - Acute myeloid leukemia
OT  - Adverse-risk
OT  - Cytarabine
OT  - Homoharringtonine
OT  - Venetoclax
COIS- The authors declare no conflict of interest.
EDAT- 2023/11/29 18:42
MHDA- 2023/11/29 18:43
PMCR- 2023/11/01
CRDT- 2023/11/29 16:13
PHST- 2023/06/22 00:00 [received]
PHST- 2023/08/24 00:00 [revised]
PHST- 2023/09/05 00:00 [accepted]
PHST- 2023/11/29 18:43 [medline]
PHST- 2023/11/29 18:42 [pubmed]
PHST- 2023/11/29 16:13 [entrez]
PHST- 2023/11/01 00:00 [pmc-release]
AID - JHA2792 [pii]
AID - 10.1002/jha2.792 [doi]
PST - epublish
SO  - EJHaem. 2023 Nov 1;4(4):1208-1211. doi: 10.1002/jha2.792. eCollection 2023 Nov.